TaiRx P/CF

What does TaiRx do? TaiRx, Inc. generates revenue through the sale of its drug products, primarily targeting domestic medical institutions in Taipei. The company's commercialized drug Zelnite is distributed via distributors to medical facilities at all levels, while its pipeline includes CVM-1118 and Rexis, which are in clinical trials. The firm focuses on developing cancer treatment drugs and sepsis adjuvant therapy drugs, with TRX-NOC, TRX-920, TRX-711, and TRX-105 forming part of its product portfolio. Revenue streams derive from both current sales of Zelnite and future potential from clinical-stage products. TaiRx's primary customers are domestic medical institutions across Taipei, which purchase Zelnite through established distributor networks. The company's R&D efforts concentrate on advancing cancer therapeutics and sepsis treatments, with CVM-1118 and Rexis representing key pipeline assets currently undergoing clinical evaluation. The firm maintains a portfolio of drug candidates including TRX-NOC, TRX-920, TRX-711, and TRX-105, though these are not yet commercially available. The company's business model centers on developing novel drug products for cancer treatment and sepsis adjuvant therapy, with Zelnite being the only product currently sold to medical institutions. Clinical-stage products CVM-1118 and Rexis are in development, while TRX-NOC, TRX-920, TRX-711, and TRX-105 represent additional pipeline candidates. Revenue is derived from Zelnite sales through distributors, with future potential from the clinical-stage pipeline. TaiRx is one of the most popular companies on Eulerpool.